Poll: Which of These Postpandemic Scenarios Is Most Likely?

The pandemic interrupted health care for many patients and saddled health care institutions with high costs. How might biosimilars improve conditions?

Which of these outcomes is probable in the wake of COVID-19?

Standard injections of pegfilgrastim biosimilars will displace widespread use of the Onpro wearable injector kit.
Use of biosimilars will expand as health care institutions seek to overcome pandemic-related deficits.
Patients presenting with untreated cancers will drive a shift to more biosimilar use.
All of these are likely to occur.
Related Videos
andre harvin
Here are the top 5 biosimilar articles for the week of May 1, 2023.
Andre Harvin, PharmD
Christine Baeder
Ian Henshaw
banner for the ophthalmology linkedin live event sponsored by the samsung bioepis in partnership with the center for biosimilars
Nabil Saba
Paul Reider
Sonia T. Oskouei, PharmD, BCMAS, DPLA0
Sonia T. Oskouei, PharmD, MS
Related Content
© 2023 MJH Life Sciences

All rights reserved.